Novel approaches for glioblastoma treatment: Focus on tumor heterogeneity, treatment resistance, and computational tools.
Journal:
Cancer reports (Hoboken, N.J.)
PMID:
32729241
Abstract
BACKGROUND: Glioblastoma (GBM) is a highly aggressive primary brain tumor. Currently, the suggested line of action is the surgical resection followed by radiotherapy and treatment with the adjuvant temozolomide, a DNA alkylating agent. However, the ability of tumor cells to deeply infiltrate the surrounding tissue makes complete resection quite impossible, and, in consequence, the probability of tumor recurrence is high, and the prognosis is not positive. GBM is highly heterogeneous and adapts to treatment in most individuals. Nevertheless, these mechanisms of adaption are unknown.
Authors
Keywords
Antineoplastic Combined Chemotherapy Protocols
Brain
Brain Neoplasms
Cancer Vaccines
Chemoradiotherapy, Adjuvant
Clonal Evolution
Computational Biology
DNA Modification Methylases
DNA Mutational Analysis
DNA Repair Enzymes
Drug Resistance, Neoplasm
Genetic Heterogeneity
Glioblastoma
Humans
Immune Checkpoint Inhibitors
Machine Learning
Microtubules
Models, Genetic
Mutation
Precision Medicine
Prognosis
Tumor Microenvironment
Tumor Suppressor Protein p53
Tumor Suppressor Proteins